Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014 Sep 01; 114(5):711-5.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cholic Acids
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Follow-Up Studies
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoprotein(a)
Male
Middle Aged
Nephelometry and Turbidimetry
Pyrroles
Steroid Metabolism, Inborn Errors
Subtilisin
Time Factors
Treatment Outcome